Biotech Unveils Two T Cell Engager Candidates
T-Cypher Bio presented preclinical data on two cancer-targeting candidates at the 2026 SITC annual meeting.
Updated on Nov. 3, 2026 in Biotech
T-Cypher Bio presented preclinical data on two T cell engager candidates, TC11 and TC25, at the 2026 SITC annual meeting in Phoenix, Arizona. Both programs are currently in IND-enabling studies and are expected to enter clinical trials in 2028.
Why it matters
Most cancer-specific proteins sit inside the cell, where antibodies and antibody-based T cell engagers cannot reach them. The company's approach targets high copy number antigens identified by scanning healthy and diseased tissue, aiming to expand the range of treatable tumor targets.
The evidence is preclinical data from a 2026 SITC poster presentation on two candidates, with clinical entry projected for 2028. Human safety and efficacy remain untested, and the candidates are still in IND-enabling studies.
The players
T-Cypher Bio
A biotechnology company developing TCR-based T cell engagers that target high copy number antigens, financed by LifeArc Ventures, Oxford Science Enterprises, Medicxi, and Borealis.
Society for Immunotherapy of Cancer (SITC)
A professional scientific society that hosts an annual meeting focused on cancer immunotherapy research and clinical development.
The details
T-Cypher Bio is developing TCR-based T cell engagers that target antigens expressed at high copy numbers. TC25, an HLA-A*02 bound peptide, appears across non-small cell lung, head and neck, and gastrointestinal tumors, while TC11 is a melanoma target detectable across diverse melanoma subtypes. Both are built on the company's T-Synapse bispecific format.
Timeline
November 4-8, 2026: 2026 SITC annual meeting in Phoenix, Arizona
November 6, 2026: TC11 poster presentation (Abstract #891)
November 7, 2026: TC25 poster presentation (Abstract #894)
2028: Both candidates expected to enter clinical trials
The Tech Race
Antibody-based bispecific T cell engagers such as blinatumomab have established the approach for surface antigens, but most cancer-specific proteins sit inside the cell. T-Cypher Bio's TCR-based candidates aim to extend this class to those intracellular targets.
Clinical entry is still about two years away, so patients will not have access to these candidates in the near term. The results provide early evidence that could shape which tumor targets future cancer therapies pursue.
The takeaway
Targeting intracellular cancer proteins remains one of the central challenges in immunotherapy, and approaches that reach them could widen treatment options. Readers should watch whether these candidates advance to human trials in 2028.
What happens next
Both candidates are expected to enter clinical trials in 2028.
Further reading
For more on the research driving this work, explore Biotech coverage.
Source note: This article includes information reported by The Manila times.
